Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarker and functional imaging profiling during antiangiogenic therapies in cancer
2008-008852-18Phase 4Completed
- Sponsor
- Medical University of Innsbruck Internal Medicine V
- Start
- Apr 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of sorafenib, sunitinib and bevacizumab in hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC) and 1 more (4 cohorts), sponsored by Medical University of Innsbruck Internal Medicine V. Started Apr 2009; status: completed.
02
Drugs
sorafenibsunitinibbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)non-small cell lung cancer (NSCLC)renal cell carcinoma (RCC)colorectal cancer (CRC)
Beyond the preview
Go deeper on 2008-008852-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-008852-18.